naltrexone and ribavirin

naltrexone has been researched along with ribavirin in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (41.67)29.6817
2010's7 (58.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dore, GJ1
Bull, J; Chua, F; Galhenage, S; Hulse, G; Jeffrey, GP; MacQuillan, G; O'Neil, G; Young, E1
Chung, HK; Lamb, K; Lin, MZ; Plemper, RK; Weisshaar, M; Yan, D1
Marjakangas, JM; Overheul, GJ; Thomassen, MC; van Cleef, KW; van Rij, RP1

Reviews

1 review(s) available for naltrexone and ribavirin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for naltrexone and ribavirin

ArticleYear
Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Drug Implants; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Prospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome

2007

Other Studies

10 other study(ies) available for naltrexone and ribavirin

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Enhancing hepatitis C treatment uptake and outcomes for injection drug users.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:1

    Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Naltrexone; Narcotic Antagonists; Patient Compliance; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome

2007
Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.
    Biochemistry, 2015, Sep-15, Volume: 54, Issue:36

    Topics: Animals; Antiviral Agents; Benzylidene Compounds; Cell Line; Coinfection; Dogs; Dose-Response Relationship, Drug; Feasibility Studies; Fenretinide; Genes, Reporter; High-Throughput Screening Assays; Humans; Influenza A virus; Luciferases, Firefly; Luciferases, Renilla; Naltrexone; Narcotic Antagonists; Neuraminidase; Respiratory Syncytial Viruses; Ribavirin; Virus Internalization; Virus Replication; Zanamivir

2015
Escape Mutations in NS4B Render Dengue Virus Insensitive to the Antiviral Activity of the Paracetamol Metabolite AM404.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:4

    Topics: Acetaminophen; Antiviral Agents; Arachidonic Acids; Biotransformation; Dengue Virus; Drug Resistance, Multiple, Viral; Gene Expression; Genes, Reporter; HeLa Cells; Humans; Luciferases; Microbial Sensitivity Tests; Mutation; Naltrexone; Ribavirin; Viral Nonstructural Proteins; Virus Replication

2016